4DMedical posts FY26 revenue growth as commercial deployment ramps up
4DMedical reports 21% FY26 revenue growth as CT:VQ gains commercial adoption, global regulatory approvals and major healthcare partnerships.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Announcements
Filter Results
| CEN March 2018 Operating Report | |||
| 13/04/18 | PRICE SENSITIVE | ||
| CEN Sue Sheldon to retire from Contact Board of Directors | |||
| 12/04/18 | |||
| CEN HY18 Shareholder letter | |||
| 06/04/18 | |||
| CEN D&O Ongoing Disclosures - Multiple | |||
| 03/04/18 | |||
| CEN D&O Ongoing Disclosure - Elena Trout | |||
| 21/03/18 | |||
| CEN Update to ASX Appendix 3A.1 (FX rate) | |||
| 21/03/18 | |||
| CEN February 2018 Operating Report | |||
| 16/03/18 | PRICE SENSITIVE | ||
| CEN D&O Ongoing Disclosures - Multiple | |||
| 08/03/18 | |||